Clinical trials: Community-acquired Bacterial Pneumonia, open to volunteers
Pneumocystis Jiroveci Pneumonia
Corticosteroids for PJP in Non-HIV Immunocompromised Adults
Pneumocystis jirovecii pneumonia (PJP) is one of the common severe complications in immunocompromised patients, with a reported mortality rate of 60-80%.
- Trial name
- CAPSTONE-PJP (NCT07152613)
- Testing
- Saline (0.9%, sterile, for infusion), Low Dose Corticosteroids, Moderate dose corticosteroids
- Volunteers
- 240 people
- Sponsor
- Qingyuan Zhan
Community Acquired Pneumonia in Children, Mycoplasma Pneumoniae
A Trial of Placebo Versus Macrolide for Mycoplasma Pneumoniae Childhood Pneumonia: MYTHIC Study
The goal of this clinical trial is to compare a placebo (a look-alike substance that contains no active drug) with a commonly used antibiotic in children with Mycoplasma pneumoniae (a specific bacterium) induced…
- Conditions
- Community Acquired Pneumonia in Children, Mycoplasma Pneumoniae, Mycoplasma Pneumoniae Pneumonia
- Trial name
- MYTHIC (NCT06325293)
- Testing
- Azithromycin Pfizer®
- Where
- 13 sites in Switzerland
- Volunteers
- 376 people
- Sponsor
- Christoph Berger
Pneumonia, Fungal Pneumonia
Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score
The FUNGAL-P study is a single-center observational study designed to derive and validate a clinical prediction score for the early identification of fungal pneumonia in adult patients presenting with pneumonia.
- Conditions
- Pneumonia, Fungal Pneumonia, Aspergillosis Pneumonia, Pulmonary Aspergillosis
- Trial name
- FUNGAL-P (NCT07681583)
- Testing
- FUNGAL-P Score Assessment
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Acute Respiratory Infections, Febrile Illnesses
The Fever Clinic Acute Respiratory Cohort
This prospective cohort study aims to characterize the natural progression and outcomes of acute respiratory infections among patients presenting to fever clinics.
- Conditions
- Acute Respiratory Infections, Febrile Illnesses, Community-acquired Pneumonia, Viral Respiratory Tract Infections
- Trial name
- FACTS (NCT07278700)
- Testing
- No intervention involved
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Fudan University
Community-Acquired Pneumonia (CAP)
Lefamulin Post-Market Surveillance Study
Community-acquired pneumonia (CAP) refers to infectious parenchymal lung inflammation acquired outside hospital settings. In China, its incidence is 7.13 per 1000 person-years, with over 10 million new cases annually.
- Trial name
- NCT07697885
- Testing
- This is a multicenter, single-arm, non-interventional study. No interventional measures will be adopted.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Pneumonia, Pneumonia Childhood
Novel Tools to Improve Management of Paediatric Community-Acquired Pneumonia - ToolCAP
The ToolCAP study aims to see if using ultrasound to look at the lungs when children have symptoms of a lung infection will safely allow doctors to improve how they treat those infections.
- Conditions
- Pneumonia, Pneumonia Childhood, Pneumonia - Bacterial, Pediatrics
- Trial name
- ToolCAP (NCT06670833)
- Testing
- Lung ultrasound, Standard of Care (SOC)
- Where
- 9 sites in Senegal, South Africa and 1 more
- Volunteers
- 4,894 people
- Sponsor
- Ecole Polytechnique Fédérale de Lausanne
Psittacosis
Adaptive RCT of Corticosteroids for Severe Chlamydia Psittaci Pneumonia in Adults
Severe community-acquired pneumonia caused by psittacosis is a form of atypical-pathogen community-acquired pneumonia that often requires critical care management.
- Trial name
- NCT07352865
- Testing
- Saline (0.9%, sterile, for infusion), low dose Methylprednisolone, Moderate dose Methylprednisolone
- Volunteers
- 100 people
- Sponsor
- Qingyuan Zhan
Community-Acquired Pneumonia
Community-acquired Pneumonia Due to Chlamydia Pneumoniae
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae. The working hypothesis is that the prevalence of C.
- Trial name
- CHLAMPAC (NCT07679789)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier de Saint-Denis
Multi Drug Resistant Infections, Pneumnia
Traditional Chinese Medicine in Multidrug-Resistant Bacterial Pneumonia
This is a multicenter prospective observational cohort study involving hospitalized adult patients with multidrug-resistant bacterial pneumonia.
- Trial name
- MDRBP-TCM (NCT07726095)
- Where
- China
- Volunteers
- 652 people
- Sponsor
- Henan University of Traditional Chinese Medicine
Pneumonia
Randomised Evaluation of COVID-19 Therapy
RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia. The treatments being investigated are: COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin…
- Trial name
- RECOVERY (NCT04381936)
- Testing
- Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine
- Where
- 16 sites in Belgium, Estonia and 14 more
- Volunteers
- 70,000 people
- Sponsor
- University of Oxford
Antimicrobial Resistance (AMR)
NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria
This is an explorative, mono-center study including prospectively collected patient samples from the University Hospital of Basel.
- Trial name
- AntiResist (NCT05017766)
- Testing
- analysis of antimicrobial resistance
- Where
- Switzerland
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland